LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5.
Preliminary experience with the efficacy and safety of dextran sulfate cellulose low-density lipoprotein (LDL) apheresis for the treatment of a 4.5-year-old girl with homozygous familial hypercholesterolemia and coronary artery disease is reported. The decrease of the most atherogenic apolipoprotein B-containing lipoproteins, low-density lipoprotein (LDL) and lipoprotein(a) (Lp [a]), were in the ranges of 63.1-68.7%, and 52.5-58.6%, respectively. The child tolerated LDL apheresis without any clinically significant complications. Therefore, she was submitted to a long-term program of treatment at intervals of 15 days. The experience suggests the possibility of an early beginning of extracorporeal treatment with LDL apheresis in children severely affected by homozygous or double heterozygous familial hypercholesterolemia.
Stefanutti
C
C
Istituto di Terapia Medica Sistematica, University of Rome La Sapienza, Policlinico Umberto I, Italy.
Notarbartolo
A
A
Colloridi
V
V
Nigri
A
A
Vivenzio
A
A
Bertolini
S
S
Bosco
G
G
Berni
A
A
Di Giacomo
S
S
Mazzarella
B
B
D001781:Blood Component Removal; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000235:genetics / Q000628:therapy; D005260:Female; D006720:Homozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000628:therapy*; D017270:Lipoprotein(a) / Q000097:blood / Q000302:isolation & purification*; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*
D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D002784:Cholesterol